PAH Registration

Pulmonary arterial hypertension is a highly complex condition that is challenging to manage. This accredited CE activity, PAH – What NPs, PAs, and Nurses Need to Know, will review the pathophysiology and classification of PAH, the association of PAH with scleroderma spectrum disorder and methamphetamine use, treatment pathways and therapies, and strategies for addressing common side effects. Disparities in care also will be highlighted.

Target Audience

The intended audience includes nurse practitioners, nurses, physician assistants and other providers involved in the management of patients with pulmonary arterial hypertension (PAH).

Objectives

After completing of the educational activity, participants should be able to:

• Identify the diagnostic criteria and classification of PAH.
• Plan effective care for patients with PAH that considers the side effect profile, method of dosing and administration, adverse events, and disparities.
• Summarize new treatment pathways and emerging therapeutic targets in the management of PAH.

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare

Nurses

1.0 ANCC contact hours.

Physician Associates

Nurse Practitioners

Commercial Support

This activity is supported by an independent medical education grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Criteria for Success

There is no fee to participate in this activity. Statements of credit will be awarded based on the participant’s attendance. A statement of credit will be available upon completion of a written paper evaluation that will be collected at the end of the activity. If you have questions about this CE activity, please contact AKH Inc at [email protected].

Faculty

Martha Kingman, FNP-C, DNP, is a Family Nurse Practitioner in the pulmonary hypertension clinic at the University of Texas Southwestern Medical Center at Dallas. She is presently serving as sub-investigator on numerous ongoing pulmonary hypertension clinical trials, and serves on several pulmonary hypertension advisory boards and steering committees. Martha is an active member of the pulmonary hypertension Professional Network and currently Vice Chair of the symposium planning committee, and has previously served on the membership and research and publications committees. She recently served on the editorial board of Advances in Pulmonary Hypertension, the journal of the Pulmonary Hypertension Association. The majority of her clinical work involves follow-up outpatient care of a large group of pulmonary hypertension patients at UTSW Medical Center. Martha has published in the area of pulmonary hypertension and has spoken at several local and national conferences. Her main area of research interest involves the safety and management of side effects of prostacyclin therapies. 

Sandra Lombardi, RN, has been the Clinical Care Coordinator for the University of California, San Diego Pulmonary Vascular Program for the past 15 years. This institution is a national referral center that is internationally recognized as a Center of Excellence by the American College of Clinical Pharmacy. Sandra has more than 30 years of experience in pulmonary and critical care, the last 20 of which has focused on pulmonary hypertension. Ms. Lombardi has been involved with direct management of pulmonary arterial hypertension (PAH) patients through her work with Accredo Health Services, in which she participated in teaching PAH patients about home IV epoprostenol and IV/SQ treprostinil use as well as inhaled therapies. She also interacts extensively with case managers and insurance companies in getting approval for PAH medication for patients. She has been a sub-investigator in multiple clinical trials involving the treatment of PAH and the impact of the disease on patients and their families.